15 results about "Lipid disorder" patented technology

The present invention relates to a dual-targeting siRNA agent, which comprises two different siRNAs targeting two different genes or pharmaceutically acceptable salts thereof, and the two different siRNAs or salts thereof are linked by a pharmaceutically acceptable ligand. The siRNA is a dsRNA composed of a sense strand and an antisense strand. The two different genes are selected from two of angiotensinogen (AGT), proprotein convertase subtilisin / kexin type 9 (PCSK9), and angiopoietin-like protein 3 (ANGPTL3). The present invention provides the application of the dual-targeting siRNA agent in the preparation of a drug for preventing or treating diseases related to hypertension or / and lipid disorders. The dual-targeting siRNA agent of the present invention can effectively inhibit the expression of two target genes in vivo simultaneously, and has the advantages of strong non-antagonistic activity and high safety. The present invention also provides siRNAs corresponding to the genes of the above dual-targeting siRNA agent and their use for preventing or treating diseases related to hypertension or / and lipid disorders.

Furan fatty acid synthesis compounds and furan fatty acid - amino acid conjugates are disclosed herein. Also disclosed herein are methods for treating non - alcoholic steatohepatitis (NASH) in a subject, comprising administering to the subject a therapeutically effective amount of any of the compounds disclosed herein. Also disclosed herein are methods for treating TG - induced pancreatitis and monogenic lipid disorders in a subject, comprising administering to the subject a therapeutically effective amount of any of the compounds disclosed herein.

The invention relates to a dual-targeting siRNA agent, which comprises two different siRNAs targeting two different genes or pharmaceutically acceptable salts thereof, the two different siRNAs or salts thereof are connected through pharmaceutically acceptable ligands, the s-RNA is dsRNA composed of a sense strand and an antisense strand, and the s-RNA is dsRNA composed of a positive-sense strand and a negative-sense strand. The two different genes are selected from two of angiotensinogen (AGT), proprotein convertase subtilisin 9 (PCSK9) and human angiopoietin-like protein 3 (ANGPTL3). The invention provides application of the dual-targeting s iRNA agent in preparation of drugs for preventing or treating diseases related to hypertension or / and lipid disorder. The dual-targeting siRNA agent can effectively inhibit expression of two target genes in vivo at the same time, and has the advantages of being high in mutual non-antagonistic activity and high in safety. The invention also provides the s iRNA of the corresponding gene of the dual-targeting s iRNA agent and application of the s iRNA to prevention or treatment of diseases related to hypertension or / and lipid disorder.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a blood fat reducing medicine in preparation of a medicine for treating pemphigus. According to the application disclosed by the invention, the hypolipidemic drug is found to be used for treating pemphigus for the first time, and by analyzing the blood fat of a PV patient, the hypolipidemic metabolism of the patient is found to be abnormal, and the oxidative stress level is related to the classical biomarker level of PV. Lipid-induced oxidative stress was confirmed by in vitro experiments using HaCaT cells treated with serum of PV patients, and it was found that it results in STAT3 activation and mitochondrial dependent apoptosis. ATO intervention can effectively reverse the pathological process: by correcting lipid metabolism disorder, ATO significantly reduces the oxidative stress level, inhibits STAT3 phosphorylation, and reduces the occurrence of mitochondrial dependent apoptosis. The invention discloses an important relationship among lipid disorder, oxidative stress, apoptosis and STAT3 activation in PV, and prompts that statins may become a potential treatment strategy for PV.

The invention discloses application of pea protein hydrolysate in intervention of gestational diabetes, and belongs to the field of biomedicine. Specifically, the invention relates to application of pea protein hydrolysate in preparation of drugs for intervening gestational diabetes. Compared with the prior art, the invention reveals that PPH can relieve GDM mouse insulin resistance and improve GDM mouse serum and placenta lipid disorder, and verifies that PPH can regulate PI3K / AKT / mTOR / PPAR gamma to improve placenta lipid accumulation and protect the placenta structure; and the placenta lipid metabolism change caused by GDM can be recovered.

The invention discloses an application of polypeptide in prevention and treatment of plateau hepatic lipid accumulation. The amino acid sequence of the polypeptide is shown as SEQ ID NO.1. The polypeptide effectively blocks abnormal lipid deposition in parenchymal liver cells and macrophages in the plateau low-oxygen environment by competitively inhibiting the function of endogenous CIRP. Animal and cell experiments show that the polypeptide can significantly improve liver fatty degeneration caused by plateau exposure, thereby providing a brand new targeted therapy strategy and drug candidate for prevention and treatment of plateau-related non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

To provide a medicine that can be used for treating diabetes mellitus, obesity, NASH and / or dyslipidemia.SOLUTION: A medicine contains a compound including a specific sequence or pharmaceutically acceptable salt thereof, which is used simultaneously or continuously and in combination separately from incretin or incretin analog for treating type 2 diabetes mellitus, obesity, dyslipidemia or NASH. The incretin or incretin analog is selected from the group consisting of GIP / GLP-1 dual agonist, glucagon, GIP, and triagonist of GLP-1, analog of oxyntomodulin, and GLP-1 agonist of oxyntomodulin.SELECTED DRAWING: None

Provided is a method for detecting a blood lipid level or a risk of developing dyslipidemia, or for determining a prevention or treatment plan for dyslipidemia, by detecting at least one lipid trait-related single nucleotide polymorphism and at least one genetic variant selected from among a group of genes consisting of LDLR, APOB, PCS, K9, LDLRAP1, and APOE in a cell collected from a subject, and detecting the level of methylation of at least one CpG site selected from among a group of genes consisting of ABCG1, DHCR24, SC4MOL, SARS, PHGDH, TXNIP, SLC7A11, GARS, CPT1A, SREBF1, PHOSPHO1SLC1A5, and SQLE in the cell collected from the subject.

The invention discloses an application of ingenol acetate or a derivative thereof and ingenol in preparation of a medicine for preventing or treating non-alcoholic steatohepatitis, and relates to the technical field of biological medicines. Experiments prove that the aromatic phenol acetate has the effect of improving non-alcoholic steatohepatitis (NASH), so that the aromatic phenol acetate can obviously relieve liver tissue damage and inhibit abnormal accumulation of lipid in the liver. The in-vivo anti-inflammatory effect is mainly realized by targeted inhibition of NLRP3 inflammasome signal axes (remarkably down-regulation of Nlrp3, Asc and Caspase-1 expression) and blocking of pannexin-1 inflammatory channels, so that release of downstream proinflammatory factors (TNF alpha, IL-1beta and IL-6) and macrophage infiltration are inhibited. The aromatic phenol acetate can be hydrolyzed and metabolized into deacetylated active product aromatic phenol through esterase in vivo, and the free hydroxyl structure of the aromatic phenol acetate can still retain the binding capacity with NLRP3 inflammasome targets as an active molecule directly acting on organs.

It relates to methods of inhibiting the expression of an ANGPTL3 gene in a subject, as well as therapeutic and prophylactic methods for treating subjects having a lipid disorder, such as a hyperlipidemia using RNAi agents, e.g., double-stranded RNAi agents, targeting the ANGPTL3 gene.

Disclosed herein, are peptides or fragments thereof capable of binding to oxidized lipids, lipid hydroperoxides or lipopolysaccharides, and a pharmaceutical composition containing the peptides or fragments and methods of using to enhance plasma anti-oxidant PON-1 activity, reduce the risk or ameliorating symptoms of a lipid-mediated inflammatory disease or treat a lipid disorder.

The present disclosure provides a combination therapy for treating a liver disease or disorder and / or a lipid disease or disorder in a subject in need thereof. Specifically, the combination therapy comprises administration of rosuvastatin and resmetirom to a subject in need thereof.

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene, and methods of using such RNAi agents to inhibit expression of PCSK9 and methods of treating subjects having a lipid disorder, such as a hyperlipidemia.

This invention discloses a 4D-printed, swallow-friendly, food-grade medicinal gel that simultaneously regulates comorbid glucose and lipid disorders, and its preparation method, belonging to the technical field of food-grade medicinal products. Starting from the complex pathological mechanism of "comorbid glucose and lipid disorders," this invention, based on the theory of "food and medicine homology" and modern systems biology, selects six food-grade medicinal raw materials (Astragalus membranaceus, Pueraria lobata, Morus alba leaf, corn silk, Dioscorea opposita, and Perilla frutescens) and combines them in a specific ratio to exert a synergistic effect of lowering blood sugar and lipids through multiple targets and pathways. Furthermore, it clarifies that its core active ingredients are quercetin, luteolin, and kaempferol, constructing a 4D-printed protective system from raw material combination to active ingredients.